<DOC>
	<DOC>NCT01519791</DOC>
	<brief_summary>This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for inducing and sustaining clinical response in the treatment of Disease Modifying Antirheumatic Drug (DMARD)-na誰ve adults with early active Rheumatoid Arthritis.</brief_summary>
	<brief_title>A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-na誰ve Adults With Early Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Subjects must have a time since diagnosis of adultonset Rheumatoid Arthritis (RA) less than 1 year as defined by the 2010 ACR/EULAR classification criteria from Screening Visit Positive Rheumatoid Factor (RF) and/or positive anticyclic Citrullinated Peptide Antibody (antiCCP) Active RA disease DMARDna誰ve Subject is na誰ve to RA related biologics A diagnosis of any other inflammatory Arthritis History of infected joint prosthesis, or other significant infection and other serious medical condition Known Tuberculosis (TB) disease or high risk of acquiring TB infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Certolizumab Pegol - Cimzia</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>